In 2 clinical trials, oveporexton shows promise in treating narcolepsy type 1 (NT1), paving the way for potential FDA approval.

administrator
Related Articles
Final Thoughts on Shingles Management
- September 9, 2025
Challenges in Shingles Prevention
- September 9, 2025